Across TCGA pan-cancer cohorts, CDHR4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDHR4 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CDHR4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDHR4 expression acts as an unfavorable survival marker.
LUSC, BRCA, and UCEC are the cancer types where CDHR4 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.